Company intelligence / Profile preview

SAGEbio

Ownership: Private
Development stage: Commercial

Overview

SAGEbio has developed a proprietary integrated platform enabling rapid discovery and manufacturing of pharmaceutical proteins. Their lead program involves a novel subunit-type vaccine for COVID‑19 currently advancing through clinical phases. The company leverages AI-driven optimization and GMP production capabilities to accelerate candidate selection and facilitate partnerships for further clinical development.

Therapeutic areas: OtherInfectious Diseases
Modalities: Subunit vaccinesMultispecific biologics (biopharmaceutical proteins)
Industry: Biotech

Drug pipeline

1 asset

anti-TL1A synbody

Preclinical

Beyond the preview

Go deeper on SAGEbio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAGEbio.

Explore the full profile